Bio-Thera Follows EU Bevacizumab Biosimilar Filing With FDA Goal Date

Biosimilar Now Accepted For Filing With Three Major Regulators

 
• By Dean Rudge

China’s Bio-Thera is continuing its journey to bring biosimilars to patients across the globe, with its BAT1706 biosimilar bevacizumab candidate accepted for filing by the US Food and Drug Administration.

China USA or United States trade and American tariffs conflict with two opposing trading partners as an economic import and exports dispute concept with 3D illustration elements
Bio-Thera Solutions is looking to break into the blockbuster US bevacizumab market as part of its global strategy. • Source: Shutterstock

More from Biosimilars

More from Products